Literature DB >> 683275

Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes.

P Raskin, R H Unger.   

Abstract

The role of glucagon in diabetes was studied in four patients with juvenile-type diabetes during continuous insulin infusion and a diet containing 150 g per day of carbohydrate. During insulin alone, plasma glucagon, measured at two-hour intervals, averaged 182 +/- 34 pg per milliliter, glucose 269 +/- 11 mg per deciliter, glucose excretion 52 +/- 8 g per 24 hours, ketone excretion 1.3 +/- 0.3 mmol per 24 hours, and urea nitrogen 12 +/- 2 g per 24 hours (mean +/- S.E.M.). Somatostatin (2 mg per day) lowered glucagon to 60 +/- 13 pg per milliliter, glucose to 111 +/- 17 mg per deciliter, glucose excretion to 1 +/- 0.7 g per 24 hours, ketone excretion to 0.5 +/- 0.2 mmol per 24 hours and urea nitrogen excretion to 8 +/- 2 g per 24 hours. Replacement of glucagon raised glucagon to 272 +/- 30 pg per milliliter, glucose to 202 +/- 20 mg per deciliter, glucose excretion to 14 +/- 7 g per 24 hours, ketone excretion to 0.8 mmol per 24 hours and urea nitrogen excretion to 11 +/- 2 g per 24 hours. In a subsequent study, similar improvement occurred on a diet of 30 g of carbohydrate daily, when absorption of dietary glucose was negligible. Hyperglucagonemia has an important role in diabetes; its correction reduces diabetic abnormalities to or toward normal.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 683275     DOI: 10.1056/NEJM197808312990901

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  55 in total

Review 1.  Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.

Authors:  Roger H Unger; Alan D Cherrington
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

2.  Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells.

Authors:  Young Lee; Eric D Berglund; Xinxin Yu; May-Yun Wang; Matthew R Evans; Philipp E Scherer; William L Holland; Maureen J Charron; Michael G Roth; Roger H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

3.  The glucagon receptor is required for the adaptive metabolic response to fasting.

Authors:  Christine Longuet; Elaine M Sinclair; Adriano Maida; Laurie L Baggio; Marlena Maziarz; Maureen J Charron; Daniel J Drucker
Journal:  Cell Metab       Date:  2008-11       Impact factor: 27.287

4.  Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice.

Authors:  Aidan S Hancock; Aiping Du; Jingxuan Liu; Mayumi Miller; Catherine L May
Journal:  Mol Endocrinol       Date:  2010-06-30

Review 5.  The role of leptin in diabetes: metabolic effects.

Authors:  Thomas H Meek; Gregory J Morton
Journal:  Diabetologia       Date:  2016-03-11       Impact factor: 10.122

Review 6.  Glucagon and diabetes: a reappraisal.

Authors:  P J Lefebvre; A S Luyckx
Journal:  Diabetologia       Date:  1979-06       Impact factor: 10.122

7.  Effects of somatostatin added to insulin in a glucose-controlled insulin infusion system.

Authors:  J L Selam; D Chenon; T C Pham; J P Gagnol; C Sany; N Thomas; G Gravagne; A Orsetti; J Mirouze
Journal:  Diabetologia       Date:  1981-08       Impact factor: 10.122

8.  Possible mechanism by which somatostatin-induced glucagon suppression improves glucose tolerance during insulinopaenia in man.

Authors:  J E Liljenquist; Z T Bloomgarden; A D Cherrington; J M Perry; D Rabin
Journal:  Diabetologia       Date:  1979-09       Impact factor: 10.122

Review 9.  The role of leptin in health and disease.

Authors:  Angela M Ramos-Lobo; Jose Donato
Journal:  Temperature (Austin)       Date:  2017-05-26

10.  Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man.

Authors:  R Rizza; C Verdonk; J Miles; F J Service; J Gerich
Journal:  J Clin Invest       Date:  1979-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.